Phase III study (daNIS-2) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) Meeting Abstract
| Authors: | O'Reilly, E. M.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wainberg, Z. A.; Wang, L. W.; Gyambibi, N.; Lopez-Martin, E. M.; Xu, K.; Macarulla, T. |
| Abstract Title: | Phase III study (daNIS-2) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304946 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS4193 |
| Notes: | Meeting Abstract: TPS4193 -- Meeting also held virtually -- Source: Wos |
